Development of donor specific antibodies after SARS-CoV-2 vaccination: What do we know so far?

Table 1 Immunological outcomes after coronavirus disease 2019 vaccination

Ref.	Number of patients vaccinated	Number of patients with pre-existing DSAs before vaccination	Type of vaccine	Number of patients who developed de novo DSAs	Number of patients with pre-existing DSAs who developed new DSAs or increased MFI post-vaccine
McCune et al[11]	100	5	Moderna 64 Pfizer 36	0	2 (Unreported whether new DSA or increased MFI)
Kueht et al[12]	96	16	Moderna Pfizer J and J	0	5 (All had increased MFIs)
Al Jurdi et al[13]	58	5	Moderna Pfizer	0	0
Russo et al[14]	82	1	Pfizer	0	0
Nishida et al[15]	63	8	mRNA vaccine (Moderna and/or Pfizer)	0	0
Massa et al[16]	61	13	Pfizer	1	Not reported
Total	460	48		1	7

DSAs: Donor specific antibodies; MFI: Mean fluorescence intensity.